Pfizer (NYSE:PFE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pfizer (NYSE:PFE – Free Report) from a hold rating to a buy rating in a research report report published on Saturday,Wall Street Zen reports.

A number of other brokerages also recently issued reports on PFE. DZ Bank downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, November 6th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $29.00 price objective on shares of Pfizer in a research report on Thursday. HSBC increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Argus set a $40.00 target price on Pfizer in a research report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Six equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $30.32.

View Our Latest Report on Pfizer

Pfizer Trading Down 0.2%

NYSE PFE opened at $28.84 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 0.67. Pfizer has a 52 week low of $23.62 and a 52 week high of $31.44. The stock has a market capitalization of $164.38 billion, a PE ratio of 9.45, a price-to-earnings-growth ratio of 1.89 and a beta of 0.31. The firm has a 50 day moving average of $28.81 and a two-hundred day moving average of $27.00.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the firm posted $0.87 EPS. The company’s quarterly revenue was down .4% compared to the same quarter last year. As a group, research analysts expect that Pfizer will post 3.04 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.0%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is currently 245.71%.

Institutional Trading of Pfizer

Hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in shares of Pfizer by 15.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after buying an additional 745,213 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of Pfizer by 10.4% during the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after buying an additional 232,528 shares in the last quarter. Leuthold Group LLC acquired a new stake in shares of Pfizer during the second quarter worth approximately $4,887,000. Park National Corp OH increased its stake in shares of Pfizer by 332.1% in the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after buying an additional 186,053 shares during the last quarter. Finally, 111 Capital bought a new stake in shares of Pfizer in the second quarter worth $3,706,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

See Also

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.